These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30311154)

  • 1. Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.
    Patil SA; Flasar MH; Lin J; Lingohr-Smith M; Skup M; Wang S; Chao J; Cross RK
    Dig Dis Sci; 2019 Jan; 64(1):60-67. PubMed ID: 30311154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF therapy is associated with decreased imaging and radiation exposure in patients with Crohn's disease.
    Patil SA; Rustgi A; Quezada SM; Flasar MH; Vandermeer F; Cross RK
    Inflamm Bowel Dis; 2013 Jan; 19(1):92-8. PubMed ID: 22508292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF therapy is associated with a reduction in radiation exposure in patients with Crohn's disease.
    Aggarwal D; Limdi JK
    Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):13-9. PubMed ID: 25341058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.
    Lewis JD; Scott FI; Brensinger CM; Roy JA; Osterman MT; Mamtani R; Bewtra M; Chen L; Yun H; Xie F; Curtis JR
    Am J Gastroenterol; 2018 Mar; 113(3):405-417. PubMed ID: 29336432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ionizing radiation exposure is still increasing in Crohn's disease: Who should be blamed?
    Magro F; Coelho R; Guimarães LS; Silva M; Peixoto A; Lopes S; Macedo G
    Scand J Gastroenterol; 2015; 50(10):1214-25. PubMed ID: 25881793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease.
    Scott FI; Johnson FR; Bewtra M; Brensinger CM; Roy JA; Reed SD; Osterman MT; Mamtani R; Chen L; Yun H; Xie F; Curtis JR; Lewis JD
    Inflamm Bowel Dis; 2019 Apr; 25(5):925-936. PubMed ID: 30535149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.
    Rubin DT; Uluscu O; Sederman R
    Inflamm Bowel Dis; 2012 Dec; 18(12):2225-31. PubMed ID: 22359399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States.
    Park KT; Colletti RB; Rubin DT; Sharma BK; Thompson A; Krueger A
    Am J Gastroenterol; 2016 Jan; 111(1):15-23. PubMed ID: 26195179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
    Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.
    Vasudevan A; Raghunath A; Anthony S; Scanlon C; Sparrow MP; Gibson PR; van Langenberg DR
    Dig Dis Sci; 2019 Jun; 64(6):1622-1631. PubMed ID: 30560332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
    Sussman DA; Kubiliun N; Mulani PM; Chao J; Gillis CA; Yang M; Lu M; T Abreu M
    Inflamm Bowel Dis; 2012 Nov; 18(11):2043-55. PubMed ID: 22241679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective.
    Miot J; Smith S; Bhimsan N
    Int J Clin Pharm; 2016 Aug; 38(4):880-7. PubMed ID: 27118462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Anti-TNFα Treatment in Crohn's Disease Patients with Abdominal Abscesses.
    Ibáñez-Samaniego L; Díaz-Fontenla F; Miranda-Bautista José ; Acosta C; Barceló I; Flores V; Echenagusía M; Camúñez F; Díaz-Redondo A; Marín-Jiménez I; Menchén L
    Hepatogastroenterology; 2015 May; 62(139):647-52. PubMed ID: 26897946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease.
    Hoekman DR; Stibbe JA; Baert FJ; Caenepeel P; Vergauwe P; De Vos M; Hommes DW; Benninga MA; Vermeire SA; D'Haens GR;
    J Crohns Colitis; 2018 Apr; 12(5):517-524. PubMed ID: 29401297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
    Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
    Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease.
    Targownik LE; Benchimol EI; Witt J; Bernstein CN; Singh H; Lix L; Tennakoon A; Zubieta AA; Coward S; Jones J; Kuenzig E; Murthy SK; Nguyen GC; Peña-Sánchez JN; Kaplan G
    Inflamm Bowel Dis; 2019 Sep; 25(10):1718-1728. PubMed ID: 31211836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.